Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Granulomatosis With Polyangiitis Treatment Market From 2025 To 2029?
The market size for the treatment of granulomatosis with polyangiitis has experienced a sturdy growth in the last few years. Projections indicate that it will scale up from $2.36 billion in 2024 to about $2.55 billion within a year, expanding at a compound annual growth rate (CAGR) of 7.9%. The expansion observed in the preceding period is a result of escalating demand for medication, increasing numbers of clinical trials, a heightened call for effective remedies, a greater focus on personalized treatment, and rising diagnoses of this particular disorder.
Predictions indicate a steep surge in the market for granulomatosis with polyangiitis treatment in the coming years. The growth is expected to reach a valuation of$3.44 billion by 2029, witnessing a compound annual growth rate (CAGR) of 7.8%. The expansion during the projection period can be credited to factors such as the rising incidence of autoimmune diseases, increased cases of granulomatosis, a surge in polyangiitis instances, and growing prevalence of immunological issues. The key trends set to mark the forecast period involve drug development advancements, progress in healthcare, innovative diagnostic techniques, evolution in treatment modalities, and the emergence of biologics and biosimilars.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21196&type=smp
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theGranulomatosis With Polyangiitis Treatment Market?
The surge in autoimmune diseases is anticipated to stimulate the expansion of the granulomatosis with polyangiitis treatment market in the future. Autoimmune ailments occur when the individual’s immune system wrongly assaults its healthy cells and tissues, leading to inflammation and impairment in numerous organs. This rise in autoimmune diseases can be attributed to environmental elements like infections, chemical substances, or contaminants, and changes in lifestyles. Treatment for granulomatosis with polyangiitis is beneficial for autoimmune illnesses by using immunosuppressive treatments like corticosteroids and cyclophosphamide that help subdue inflammation and deter organ harm, making it vital to have initial intervention and personalized therapy for controlling other autoimmune disorders with similar traits. For instance, in June 2023, as per a report issued by the Office for National Statistics, a government department based in the UK, the global populace with multiple sclerosis (an autoimmune disease) in 2023 was 2.9 million, an increase from 2.8 million in 2022. This rise in autoimmune diseases is thus propelling the expansion of the granulomatosis with polyangiitis treatment market.
Which Segments in the Granulomatosis With Polyangiitis Treatment Offer the Most Growth?
The granulomatosis with polyangiitis treatmentmarket covered in this report is segmented –
1) By Drug Type: Steroids; Immunosuppressant; Other Drug Types
2) By Treatment Type: Immunosuppressants; Corticosteroids
3) By Route Of Administration: Oral; Intravenous
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Steroids: Prednisone; Methylprednisolone; Dexamethasone; Hydrocortisone
2) By Immunosuppressants: Cyclophosphamide; Methotrexate; Azathioprine; Mycophenolate mofetil; Rituximab
3) By Other Drug Types: Plasma Exchange Therapy; Intravenous Immunoglobulin (IVIG); Biologic Agents; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21196&type=smp
What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theGranulomatosis With Polyangiitis Treatment Market?# Market?
North America was the largest region in the granulomatosis with polyangiitis treatment market in 2024. The regions covered in the granulomatosis with polyangiitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Current Market Growth and Trends in the Granulomatosis With Polyangiitis Treatment Industry?
Key players within the granulomatosis with polyangiitis treatment sphere are directing their energies towards the advancement of novel products, including oral corticosteroids, with the aim of offering patients improved treatment protocols which not only better manage the disease but also lessen the enduring side effects of steroid usage. Oral corticosteroids, drugs which alleviate inflammation and suppress immune response, are frequently utilized in the treatment of allergy, autoimmune, and inflammatory disorders. For example, in October 2024, UK pharmaceutical giant, AstraZeneca plc, delivered the news that Fasenra (bevacizumab) received approval within the European Union, a consortium of European nations focused on political and economic collaboration, for supplementary treatment of adult patients with either relapsing or unmanageable eosinophilic granulomatosis with polyangiitis (EGPA). This approval comes on the heels of affirmative results from the MANDARA Phase III trial, which attested to Fasenra’s effectiveness in inducing remission and lessening dependence on oral corticosteroids among EGPA patients.
View the full report here:
What Are the Key Elements That Define the Granulomatosis With Polyangiitis Treatment Market?
Granulomatosis with Polyangiitis (GPA) treatment involves the use of medications to control inflammation, suppress the immune system, and prevent organ damage. Granulomatosis with polyangiitis (GPA) is a rare autoimmune disorder causing inflammation of small to medium blood vessels, leading to restricted blood flow and tissue damage, particularly in the respiratory tract and kidneys. Treatment primarily involves immunosuppressive therapies, such as corticosteroids and biologics, to reduce inflammation and prevent organ damage.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21196
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model